Clinical Study on the Treatment of Pelvic Pain With Wearable Dual-band LED Device
Launched by PEKING UNIVERSITY THIRD HOSPITAL · May 13, 2025
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment for pelvic pain, which can include painful menstrual cramps (dysmenorrhea) and ongoing pelvic discomfort (chronic pelvic pain). The researchers are looking for women who experience this type of pain to wear a special device that uses low-level light therapy on specific areas of their body. This therapy will be done during times when they are not menstruating. The goal is to see if this treatment can help reduce their pain and improve related health indicators.
To participate, women must be experiencing pelvic pain, but those with irregular menstrual cycles, inflammatory diseases, or who are pregnant, as well as those with light allergies, cannot join the study. If eligible, participants can expect to use the wearable device and will be monitored for changes in their pain and overall health during the trial. The study is currently recruiting participants, so this could be a great opportunity for those looking for relief from pelvic pain.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • pelvic pain
- Exclusion Criteria:
- • Irregular menstrual cycles;
- • Inflammatory disease;
- • pregnant;
- • Light allergy;
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported